Efficacy and safety of botulinum toxin injection in reducing deltoid muscle hypertrophy

With the increasing demand for body contouring, botulinum toxin (BTX) injection is being widely used off-label for muscular hypertrophy. However, to the best of our knowledge, no study has investigated the clinical efficacy of BTX type A (BTX-A) in deltoid muscle hypertrophy. This study was conducted to evaluate the efficacy and safety of intramuscular injection of BTX in reducing deltoid muscle hypertrophy. Overall, 10 patients with bilateral deltoid muscle hypertrophy were treated with an intramuscular injection of prabotulinum toxin A, with a total of 50 units [U] administered per patient. As measured by ultrasonography, the thickness of the deltoid muscles was significantly decreased at weeks 2 and 12. In addition, the clinical assessment score by blinded investigators was improved after the treatment; however, patients' satisfaction scores were relatively low. No major complications were reported. Therefore, intramuscular injection of BTX-A seems to be a candidate for novel treatment option for deltoid muscle hypertrophy. Further larger clinical studies are warranted to confirm the efficacy of BTX-A.

Automated summary

This study evaluated the efficacy and safety of intramuscular injection of BTX in reducing deltoid muscle hypertrophy, showing a significant decrease in muscle thickness and improvement in clinical assessment scores post-treatment, although patient satisfaction scores were relatively low. No major complications were reported, suggesting that BTX-A injection may be a novel treatment option for deltoid muscle hypertrophy. Further larger clinical studies are warranted to confirm its efficacy.